Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 2/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | PCSK9 | Q8NBP7 | 4/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | CDK1 | P06493 | 2/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1065266 | 0.86 | MAPK14 (0.39) | CDK5CDK5R1SCN9AMAPK8RORC | |
| SCHEMBL1065493 | 0.83 | MAPK14 (0.40) | CDK5CDK5R1NPC1KDM4EALDH1A1 | |
| SCHEMBL6911074 | 0.83 | BRD4 (0.39) | MAPK8RORCGRIN1GRIN2B | |
| SCHEMBL1067521 | 0.82 | RORC (0.36) | SCN9AMAPK8RORCPIK3CA | |
| SCHEMBL1063681 | 0.82 | MAPK14 (0.48) | CDK5CDK5R1NPC1KDM4EALDH1A1 | |
| SCHEMBL1066565 | 0.82 | MAPK13 (0.40) | CDK5CDK5R1NPC1KDM4EALDH1A1 | |
| SCHEMBL1063624 | 0.82 | ALDH1A1 (0.37) | CDK5CDK5R1NPC1KDM4EALDH1A1 | |
| SCHEMBL1061554 | 0.79 | CCNT1 (0.38) | CDK5CDK5R1SCN9ACDK1GRIN1 | |
| SCHEMBL1063029 | 0.78 | HSP90AB1 (0.46) | KDM4EALDH1A1RORCMEN1KMT2A | |
| SCHEMBL6327181 | 0.77 | MAPK14 (0.47) | KDM4EALDH1A1HPGDKMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2404603-A1 | Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases | Glaxosmithkline LLC (US) | 2012-01-11 | — | — | EP | claimed |
| US-20040116697-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2004-06-17 | — | — | US | claimed |
| EP-2404603-A1 | Novel trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds for the treatment of CSBP/p38 kinase mediated diseases | Glaxosmithkline LLC (US) | 2012-01-11 | — | — | EP | disclosed |
| US-8058282-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy | GLAXOSMITHKLINE LLC (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058282-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy | GLAXOSMITHKLINE LLC (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058282-B2 | 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds and compositions for use in therapy | GLAXOSMITHKLINE LLC (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110046109-A1 | 2,4,8-TRISUBSTITUTED-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE COMPOUNDS AND COMPOSITIONS FOR USE IN THERAPY | GLAXOSMITHKLINE LLC (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046109-A1 | 2,4,8-TRISUBSTITUTED-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE COMPOUNDS AND COMPOSITIONS FOR USE IN THERAPY | GLAXOSMITHKLINE LLC (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046109-A1 | 2,4,8-TRISUBSTITUTED-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE COMPOUNDS AND COMPOSITIONS FOR USE IN THERAPY | GLAXOSMITHKLINE LLC (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110009625-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009625-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-01-13 | — | — | US | disclosed |
| US-7314934-B2 | 4-amino substituted-6-aryl/heteroaryl substituted-2-methylsulfanyl-pyrimidine-5-carbaldehyde intermediates | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314934-B2 | 4-amino substituted-6-aryl/heteroaryl substituted-2-methylsulfanyl-pyrimidine-5-carbaldehyde intermediates | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-01 | — | — | US | disclosed |
| US-7314934-B2 | 4-amino substituted-6-aryl/heteroaryl substituted-2-methylsulfanyl-pyrimidine-5-carbaldehyde intermediates | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-01 | — | — | US | disclosed |
| EP-1333833-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20050203109-A1 | Novel Compounds | SMITHKLINE BEECHAM CORPORATION | 2005-09-15 | — | — | US | disclosed |
| US-20040209901-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION | 2004-10-21 | — | — | US | disclosed |
| US-20040116697-A1 | Novel compounds | GLAXOSMITHKLINE LLC | 2004-06-17 | — | — | US | disclosed |
| EP-1333833-A2 | NOVEL COMPOUNDS | SmithKline Beecham Corporation (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002059083-A2 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046109-A1 | 2,4,8-TRISUBSTITUTED-8H-PYRIDO[2,3-D]PYRIMIDIN-7-ONE COMPOUNDS AND COMPOSITIONS FOR USE IN THERAPY | MAPKAPK2, MAPK8, CREBBP | CDK5 42/4885CDK5R1 161/4885NPC1 2076/4885 |
| US-20110009625-A1 | NOVEL COMPOUNDS | MAPKAPK2, CREBBP, CDC42BPB | CDK5 92/4885CDK5R1 140/4885NPC1 1751/4885 |
| US-20040209901-A1 | Novel compounds | MAPKAPK2, MAPKAPK3, MAPK7 | CDK5 121/4885CDK5R1 164/4885NPC1 2122/4885 |
| US-20050203109-A1 | Novel Compounds | MAPKAPK2, CREBBP, CDC42BPB | CDK5 92/4885CDK5R1 140/4885NPC1 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.